The FDA issues 510(k) clearance for Dexcom’s (NASDAQ:DXCM) G6 Pro Continuous Glucose Monitoring (CGM) System for patients at least two years old.
The company says the single-use device gathers
real-time glucose data (at five-minute intervals) over a 10-day period
in both a blinded and unblinded mode.
Shipments will commence in Q1 2020.
https://seekingalpha.com/news/3504443-fda-oks-dexcom-g6-pro-cgm-system
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.